Light-Activated Intracellular Acidosis Therapy May Cause Cancer Cells to Undergo Rapid Apoptosis Vitanova Biomedical Inc., a San Antonio-based early-stage biotechnology company, is currently conducting pre-clinical trials on a proprietary Light-Activated Intracellular Acidosis […]
Immix Biopharma Welcomes Two Oncologists to Medical Advisory Board
Immix Therapies Enhance Apoptotic Activity of FDA-Approved Agents by 5X and Catalyze Total Shift in Tumor Micro-Environment Immix Biopharma, Inc., a Los Angeles-based clinical-stage biopharmeceutical company developing therapies for high unmet medical […]
Immunicom Developing Subtractive Device-Based Cancer Treatment Platform
Blood-Filtering Device Treats Cancer By Removing Blocking Proteins Released By Cancer Cells Immunicom Inc., a San Diego-based immuno-oncology company, is developing a proprietary subtractive device-based technology platform as a novel approach to […]
Global Cancer Initiative Launched. Consortium Organized
Initiated by a global think tank, Klosters Institute, the objective is to create a consortium committed to fostering collaboration. Research to assessing connectivity the global cancer ecosystem and published in a Cancer […]
CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study
CEL-SCI Corporation recently announced that no further patient enrollment is required in the pivotal Phase 3 head and neck cancer study of its investigational immunotherapy, Multikine. The accrual and treatment phases of […]
NovoCure’s Non-Invasive Cancer Treatment to Target Solid Tumors
Novocure is an oncology company working to develop a novel cancer treatment utilizing a proprietary therapy called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid […]
TapImmune Completes Patient Enrollment in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer
TapImmune Inc., a Florida-based leading clinical-stage immuno-oncology company recently announced that it has enrolled the final patient in a randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV200 for […]
UroGen Pharma’s Immunotherapy Product to Treat High-Grade Non-Muscle Invasive Bladder Cancer
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. They currently have an innovative and […]
